Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis

Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE (Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.

Kirti Ganorkar, CEO – India Business, Sun Pharma, said, “Erosive Esophagitis is a serious condition that greatly affects patients’ quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients’ quality of life.”

Fexuprazan was evaluated in a double-blind, double-dummy, comparative Phase 3 study in adult Indian population. The primary efficacy measure was healing of Erosive Esophagitis which was confirmed endoscopically. The study met its primary endpoint. Over 95% of the patients achieved Erosive Esophagitis healing by 8 weeks. Fexuprazan was found to be well tolerated in India patients.